Patent Grant
10610470
Antiperspirants based on aluminum or aluminum/zirconium salts are known. These materials function as antiperspirants by plugging pores thereby blocking sweat release. Antiperspirant compositions containing aluminum or aluminum-zirconium salts tend to exhibit polymerization of these salts over time, forming species with molecular weights ranging from about 500 to about 500,000 g/mol. In general, lower molecular weight species have greater antiperspirant effect than higher molecular weight species. Without being bound by theory, it is believed that the smaller molecules more readily and more effectively occlude sweat pores, thereby producing the desired antiperspirant effect. Maintaining a relatively low molecular weight and avoiding excessive polymerization enhances the antiperspirant effect and moreover lowers the amount of antiperspirant salt which necessary to control perspiration.
Underarm deodorants control odor by eliminating the bacteria that cause odor. Conventional antiperspirant salts tend to be acidic in aqueous solution, a property which makes them effective bacteriocides, thereby providing a deodorant benefit, but which can also cause skin irritation.
There is a need for additional antiperspirant active agents that provide molecular weight complexes of a size capable of plugging pores to block sweat, that provide deodorant/antibacterial efficacy, and that are less irritating to the skin than the acidic salts in conventional antiperspirants.
The invention provides a zinc-lysine complex, sometimes referred to herein as ZLC, formed from a mixture of zinc oxide and lysine hydrochloride. The chemical structure of ZLC is [Zn(C6H14N2O2)2Cl]+Cl−. This salt has key features (e.g., conductivity, hydrolysis reaction and protein flocculation) which make it competitive with commercial antiperspirant salts.
Like the existing aluminum or aluminum-zirconium antiperspirant salts, ZLC forms precipitates under sweat conditions that can plug the pores and block sweat release. In the presence of protein, the ZLC will flocculate and plug the sweat glands. As the amount of water increases, rather than going into or remaining in solution as the solution becomes more dilute, as would typically be the case for an ionic complex, the ZLC complex hydrolyzes, to provide a relatively insoluble zinc oxide precipitate, thereby permitting further plugging of the pores and/or controlled deposition of zinc oxide on the skin. The zinc is antibacterial, and so in addition to providing a precipitate which blocks sweat release from the pores, it provides a deodorant benefit by reducing odor-causing bacteria. Finally, the ZLC may be provided in a formulation which is approximately pH neutral, which is closer in pH to skin pH than the currently-used antiperspirant salts, or current deodorant formulations.
The invention thus provides ZLC per se, as well as personal care products that deliver ZLC to the skin, and methods of making and using ZLC. In one embodiment, the invention provides antiperspirant or deodorant compositions that comprise ZLC. As the ZLC antibacterial properties, the invention also encompasses other personal care compositions for application to the skin, for example hand soaps or body washes, comprising a ZLC, e.g., any of Complex 1, et seq. and/or precursors thereof. The invention further provides methods of reducing sweat comprising applying the composition to skin, and methods of killing bacteria comprising contacting the bacteria with the composition.
Further areas of applicability of the present invention will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
The present invention will become more fully understood from the detailed description and the accompanying drawings, wherein
The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.
The invention therefore provides, in a first embodiment, a zinc-lysine complex having the formula [Zn(C6H14N2O2)2Cl]+Cl− (sometimes referred to herein as “ZLC”), e.g.,
In a further embodiment, the invention provides a personal care composition (Composition 2) for application to the skin which comprises ZLC, e.g., any of Complex 1, et seq., as described above, in combination with a cosmetically acceptable carrier. For example, the invention provides
In a further embodiment, the invention provides an oral care composition (Composition 3) for application to the oral cavity which comprises ZLC, e.g., any of Complex 1, et seq., as described above, in combination with an orally acceptable carrier. For example, the invention provides
The invention further provides methods of reducing perspiration comprising applying an antiperspirant effective amount of any of Composition 2, et seq. to the skin, methods of reducing body odor comprising applying a deodorant-effective amount of any of Composition 2, et seq. to the skin, and methods of killing bacteria comprising contacting the bacteria with an antibacterially effective amount of a ZLC, e.g., any of Complex 1, et seq. for example contacting with e.g., any of Composition 2, et seq.
The invention further provides a method of making a composition comprising ZLC, e.g., any of Complex 1, et seq. comprising combining zinc oxide and lysine hydrochloride in aqueous solution, and optionally adding this mixture to ethanol and isolating the crystalline precipitate thus obtained.
The invention further provides (i) the use of a ZLC, e.g., any of Complex 1, et seq., to kill bacteria, reduce perspiration, and/or reduce body odor; (ii) the use of a ZLC, e.g., any of Complex 1, et seq., in the manufacture of a composition to kill bacteria, reduce perspiration, and/or reduce body odor; and (iii) ZLC, e.g., any of Complex 1, et seq., for use in killing bacteria, reducing perspiration, and/or reducing body odor.
It will be understood that, although the ZLC may be primarily in the form of a complex, there may be some degree of equilibrium with zinc oxide and lysine hydrochloride precursor materials, so that the proportion of material which is actually in complex compared to the proportion in precursor form may vary depending on the precise conditions of formulation, concentration of materials, pH, presence or absence of water, presence or absence of other charged molecules, and so forth.
ZLC, e.g., any of Complex 1, et seq., can be incorporated into a suitable base, for example a stick, roll-on, spray or aerosol for application to the underarm. Following application, the ZLC in the presence of charged molecules such as proteins found on the skin, the ZLC will flocculate, forming plugs which block sweat release. Additional water from sweat can moreover dilute the formulation, causing the complex to decompose, resulting in precipitation of zinc oxide, which can reduce sweat and odor as described above. Similarly, if the ZLC is provided in a hand soap or body wash base, the dilution of the ZLC upon washing results in a thin deposition of zinc oxide on the skin, providing an antibacterial effect.
As used herein, the term antiperspirant can refer to any material that can form a plug in a pore to reduce sweating, or antiperspirant refers to those materials classified as antiperspirants by the Food and Drug Administration under 21 CFR part 350. Antiperspirants may also be deodorants, particularly in the case of this invention, as zinc has antibacterial properties and can reduce odor-causing bacteria on the skin.
The composition can include the ZLC, e.g., any of Complex 1, et seq. and/or precursors thereof, for example zinc oxide and lysine hydrochloride. In one embodiment, the ZLC is prepared at room temperature by mixing the precursors in an aqueous solution. The in situ formation provides ease of formulation. The precursors can be used instead of first having to form the ZLC. In another embodiment, the water permitting formation of the ZLC, e.g., any of Complex 1, et seq. from the precursor comes from sweat that comes into contact with the composition after application.
In certain embodiments, the amount of ZLC, e.g., any of Complex 1, et seq. in the composition of the invention, e.g., any of Compositions 2, et seq., is 0.05 to 40% by weight of the composition. In certain embodiments, precursors, e.g., zinc oxide and lysine hydrochloride, are present in amounts such that when combined into the ZLC, e.g., any of Complex 1, et seq., the ZLC, e.g., any of Complex 1, et seq. would be present in an amount of 0.05 to 10% by weight of the composition. In either of these embodiments, the amount of the ZLC, e.g., any of Complex 1, et seq. can be varied for the desired purpose, such as an antibacterial agent or as an antiperspirant. In other embodiments, the amount of the ZLC, e.g., any of Complex 1, et seq. is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, at least 1, at least 2, at least 3, or at least 4 up to 10% by weight of the composition. In other embodiments, the amount of the ZLC, e.g., any of Complex 1, et seq. is less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2, less than 1, less than 0.5 to 0.05% by weight of the composition. In other embodiments, the amounts are 0.05 to 5%, 0.05 to 4%, 0.05 to 3%, 0.05 to 2%, 0.1 to 5%, 0.1 to 4%, 0.1 to 3%, 0.1 to 2%, 0.5 to 5%, 0.5 to 4%, 0.5 to 3%, or 0.5 to 2% by weight of the composition.
In some embodiments, the total amount of zinc in the composition is 0.05 to 10% by weight of the composition. In other embodiments, the total amount of zinc is at least 0.1, at least 0.2, at least 0.3, at least 0.4, at least 0.5, or at least 1 up to 8% by weight of the composition. In other embodiments, the total amount of zinc in the composition is less than 5, less than 4, less than 3, less than 2, or less than 1 to 0.05% by weight of the composition.
In certain embodiments, the composition is anhydrous. By anhydrous, there is less than 5% by weight water, optionally less than 4, less than 3, less than 2, less than 1, less than 0.5, less than 0.1 down to 0% by weight water.
When provided in an anhydrous composition, precursors, e.g., zinc oxide and lysine hydrochloride, will not significantly react to form the ZLC, e.g., any of Complex 1, et seq. When contacted with a sufficient amount of water, which can be in the form of sweat, the precursors will then react to form the ZLC, e.g., any of Complex 1, et seq. The ZLC, e.g., any of Complex 1, et seq. when introduced into a sweat duct will flocculate with protein and/or hydrolyze with water and/or sweat to form a precipitate to block the sweat duct.
In certain embodiments, the ZLC, e.g., any of Complex 1, et seq. can have a conductivity of greater than 8000, optionally greater than 9000, greater than 10,000, or greater than 12,000 μS/cm
The composition can be any type of composition. In certain embodiments, the composition is any composition in which it is desired to include an antibacterial agent for application to the skin. Examples of such compositions include, but are not limited to, personal care compositions, antiperspirants, deodorants, body washes, shower gels, bar soaps, shampoo, hair conditioners, cosmetics.
The carrier represents all other materials in the composition other than the ZLC, e.g., any of Complex 1, et seq. or the zinc oxide and amino acid hydrohalide. The amount of carrier is then the amount to reach 100% by adding to the weight of the ZLC, e.g., any of Complex 1, et seq. or the zinc oxide and amino acid hydrohalide.
For antiperspirant/deodorant compositions, the carrier can be any carrier that is used for antiperspirants/deodorants. The carrier can be in the form of a stick, a gel, a roll-on, or an aerosol. For stick formulations, the carrier may include oils and/or silicones and gelling agents. An example of a formulation can be found in US2011/0076309A1, incorporated by reference herein.
Optional ingredients that can be included in an antiperspirant and/or deodorant formulation of the compositions of the invention include solvents; water-soluble alcohols such as C2-8 alcohols including ethanol; glycols including propylene glycol, dipropylene glycol, tripropylene glycol and mixtures thereof; glycerides including mono-, di- and triglycerides; medium to long chain organic acids, alcohols and esters; surfactants including emulsifying and dispersing agents; amino acids including glycine; structurants including thickeners and gelling agents, for example polymers, silicates and silicon dioxide; emollients; fragrances; and colorants including dyes and pigments. If desired, an antiperspirant and/or deodorant agent additional to the ZLC, e.g., any of Complex 1, et seq. can be included, for example an odor reducing agent such as a sulfur precipitating agent, e.g., copper gluconate, zinc gluconate, zinc citrate, etc.
The antiperspirant compositions can be formulated into topical antiperspirant and/or deodorant formulations suitable for application to skin, illustratively a stick, a gel, a cream, a roll-on, a soft solid, a powder, a liquid, an emulsion, a suspension, a dispersion or a spray. The composition can comprise a single phase or can be a multi-phase system, for example a system comprising a polar phase and an oil phase, optionally in the form of a stable emulsion. The composition can be liquid, semi-solid or solid. The antiperspirant and/or deodorant formulation can be provided in any suitable container such as an aerosol can, tube or container with a porous cap, roll-on container, bottle, container with an open end, etc.
The compositions can be used in a method to reduce sweating by applying the composition to skin. In certain embodiments, the application is to axilla. Also, the compositions can be used to kill bacteria by contacting bacteria with the composition. For example, in one embodiment, the combination of the amino acid or amino acid hydrohalide with the zinc oxide increases the availability of zinc ions, which can then kill bacteria and reduce sweat.
Thus the invention provides (i) a method for controlling perspiration comprising applying to skin an antiperspirant effective amount of a formulation of any embodiment embraced or specifically described herein, e.g., any of Compositions 1 et seq.; and (ii) a method for controlling odor from perspiration comprises applying to skin a deodorant effective amount of a formulation of any embodiment embraced or specifically described herein, e.g., any of Compositions 1 et seq.
Unless stated otherwise, all percentages of composition components given in this specification are by weight based on a total composition or formulation weight of 100%.
Unless otherwise specifically identified, the ingredients for use in the compositions and formulations of the present invention are preferably cosmetically acceptable ingredients. By “cosmetically acceptable” is meant suitable for use in a formulation for topical application to human skin. A cosmetically acceptable excipient, for example, is an excipient which is suitable for external application in the amounts and concentrations contemplated in the formulations of this invention, and includes for example excipients which are “Generally Recognized as Safe” (GRAS) by the United States Food and Drug Administration.
The compositions and formulations as provided herein are described and claimed with reference to their ingredients, as is usual in the art. As would be evident to one skilled in the art, the ingredients may in some instances react with one another, so that the true composition of the final formulation may not correspond exactly to the ingredients listed. Thus, it should be understood that the invention extends to the product of the combination of the listed ingredients.
The general reaction for formation of ZLC is as follows:
ZnO+2(Lysine.HCl)→[Zn(Lysine)2Cl]+Cl−.2H2O (ZLC)
A 2:1 molar ratio of ZnO:Lysine.HCl suspension is prepared with stirring at room temperature for about 12 hours. The mixture is centrifuged. 1 ml of supernatant is transferred into an NMR tube. The NMR tube is then placed in a closed test tube filled with ethanol for crystal growth. A number of colorless, cubic crystals are formed after a week. The crystal structure of ZLC crystal is determined by single crystal X-ray diffraction. ZLC has an empirical formula as C12H32N4O6Cl2Zn with molecular weight of 464.44 g/mol. In this complex, Zn cation is coordinated by two two lysine ligands with two N atoms from NH2 groups and O atoms from carboxylic groups in an equatorial plane. It displays a distorted square-pyramidal geometry with the apical position occupied by a Cl atom. This structure gives rise to a positive cation moiety, to which a Cl anion is combined to form an ionic salt.
Laboratory Scale-Up Synthesis of Pure ZLC Powder:
2 mole of LysineHCl is dissolved in 1000 ml DI water with stirring at room temperature, 1 mole of solid ZnO is added slowly to the LysineHCl solution with stirring and the stirring is continued at RT overnight (about 12 hours). The suspension solution is centrifuged at high speed for 15 mins. The supernatant is slowly poured into EtOH. A precipitate is formed immediately. Approximately 5-8 ml EtOH is needed to get 1 g powder. The EtOH solvent with powder is filtered, and an off-white powder is obtained. The powder is placed in a 50° C. oven for drying and an 88% yield of product is obtained. PXRD confirms the purity of ZLC powder compared to ZLC crystal (
Hydrolysis Reaction:
A 185 mg/ml ZLC solution is prepared and diluted several-fold and aged in a 37° C. oven over 5 hours for turbidity studies. A white precipitate forms as the solution is diluted. Turbidity of the solutions is measured using a nephelometer, results being given in nephelometric turbidity units (NTU). Table 1 shows a comparison of pH and turbidity before and after aging, showing an increase in turbidity with dilution and with aging:
The precipitates formed in the 8×, 16× and 32× diluted solutions are collected by centrifugation and identified as crystalline ZnO by PXRD. From the supernatant, a single crystal is grown and shown by X-ray diffraction to be Lysine Monohydrochloride Dihydrate (Lysine.HCl.2H2O). These data indicate that the ZLC complex disassociates upon dilution, with consequent precipitation of zinc oxide.
The mechanism of the ZLC hydrolysis reaction can be expressed as
[Zn(Lysine)2Cl]+Cl−.2H2O+H2O→ZnO+Lysine.HCl.2H2O
In an underarm product, a mixture of ZnO+lysine HCl, in the presence of sweat, will form ZLC, which will enter the sweat duct and form a plug of ZnO.
Flocculation:
Another mechanism by which the ZLC blocks sweat release involves flocculation of ZLC in the presence of protein. Bovine Serum Albumin (BSA) is used as the protein in this study. Control solution (DI water) and three 1% BSA aqueous solutions with different pH are prepared as set forth on Table 2.
ZLC powder is added to the above samples to study the interaction between ZLC and BSA and to determine whether ZLC has astringent properties, i.e., whether it can form a precipitate and thus behave as an antiperspirant. Turbidity and pH of solutions are measured 5 hours after the mixtures were placed in a 37° C. oven, and the results are shown in Table 3.
Thus, in the sweat duct (pH=5-7), ZLC will hydrolyze to insoluble ZnO to physically block the sweat ducts. In addition, ZLC also has the ability to flocculate proteins, such as BSA, in the sweat, thus enhancing the formation of “plugs” in the sweat ducts.
As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
Unless otherwise specified, all percentages and amounts expressed herein and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the active weight of the material.
This application is Continuation Application filed under 35 U.S.C. § 111 of U.S. application Ser. No. 14/653,314, filed on Jun. 18, 2015, which is a United States National Stage Application under 35 U.S.C. § 371 of International Application PCT/US2012/070498, filed on Dec. 19, 2012, the contents of each of which are hereby incorporated by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2503280 | Lockwood | Apr 1950 | A |
| 2507088 | Bradley | May 1950 | A |
| 2527686 | Sandberg | Oct 1950 | A |
| 2893918 | Abramson | Jul 1959 | A |
| 3260744 | Kenkichi | Jul 1966 | A |
| 3320174 | Rubinfeld | May 1967 | A |
| 3372188 | Terence | Mar 1968 | A |
| 3535421 | Briner | Oct 1970 | A |
| 3538230 | Morton | Nov 1970 | A |
| 3678154 | Briner | Jul 1972 | A |
| 3741911 | Shane | Jun 1973 | A |
| 3862307 | Giulio | Jan 1975 | A |
| 3937807 | Haefele | Feb 1976 | A |
| 3941818 | Abdel-Monem | Mar 1976 | A |
| 3959458 | Agricola et al. | May 1976 | A |
| 4051234 | Gieske et al. | Sep 1977 | A |
| 4316824 | Pancheri | Feb 1982 | A |
| 4339432 | Ritchey et al. | Jul 1982 | A |
| 4340583 | Wason | Jul 1982 | A |
| 4487757 | Kiozpeoplou | Dec 1984 | A |
| 4565693 | Marschner | Jan 1986 | A |
| 4599152 | Ashmead | Jul 1986 | A |
| 4684528 | Godfrey | Aug 1987 | A |
| 4687663 | Schaeffer | Aug 1987 | A |
| 4842847 | Amjad | Jun 1989 | A |
| 4866161 | Sikes et al. | Sep 1989 | A |
| 4885155 | Parran, Jr. et al. | Dec 1989 | A |
| 5004597 | Majeti et al. | Apr 1991 | A |
| 5061815 | Leu | Oct 1991 | A |
| 5156845 | Grodberg | Oct 1992 | A |
| 5188821 | Gaffar et al. | Feb 1993 | A |
| 5192531 | Gaffar et al. | Mar 1993 | A |
| 5470876 | Proctor | Nov 1995 | A |
| 5504055 | Hsu | Apr 1996 | A |
| 5643559 | Eigen et al. | Jul 1997 | A |
| 5698724 | Anderson et al. | Dec 1997 | A |
| 5707679 | Nelson | Jan 1998 | A |
| 5714447 | Jones et al. | Feb 1998 | A |
| 5911978 | Carr et al. | Jun 1999 | A |
| 5993784 | Hill | Nov 1999 | A |
| 6121315 | Nair et al. | Sep 2000 | A |
| 6156293 | Jutila et al. | Dec 2000 | A |
| 6346231 | Ascione et al. | Feb 2002 | B1 |
| 6607711 | Pedersen | Aug 2003 | B2 |
| 6685920 | Baig et al. | Feb 2004 | B2 |
| 6969510 | Holerca et al. | Nov 2005 | B2 |
| 8067627 | Newsome et al. | Nov 2011 | B2 |
| 8247398 | Goel | Aug 2012 | B2 |
| 9572756 | Liu | Feb 2017 | B2 |
| 9675823 | Liu | Jun 2017 | B2 |
| 9757316 | Pan | Sep 2017 | B2 |
| 9763865 | Pan | Sep 2017 | B2 |
| 9775792 | Liu | Oct 2017 | B2 |
| 9913784 | Szewczyk | Mar 2018 | B2 |
| 9980890 | Pan | May 2018 | B2 |
| 10105303 | Pan | Oct 2018 | B2 |
| 10130571 | Szewczyk | Nov 2018 | B2 |
| 10195125 | Pan | Feb 2019 | B2 |
| 20030077332 | Godfrey | Apr 2003 | A1 |
| 20040033916 | Kuzmin et al. | Feb 2004 | A1 |
| 20040042978 | Embro | Mar 2004 | A1 |
| 20040122088 | Newsome et al. | Jun 2004 | A1 |
| 20040198998 | Holerca et al. | Oct 2004 | A1 |
| 20060024252 | Esposito et al. | Feb 2006 | A1 |
| 20070071698 | Doss | Mar 2007 | A1 |
| 20090220444 | Teckenbrock et al. | Sep 2009 | A1 |
| 20100021573 | Gonzalez et al. | Jan 2010 | A1 |
| 20100266480 | Huang | Oct 2010 | A1 |
| 20100330163 | Soparkar | Dec 2010 | A1 |
| 20110076309 | Misner et al. | Mar 2011 | A1 |
| 20110229536 | Kvitnitsky et al. | Sep 2011 | A1 |
| 20130017240 | Porter et al. | Jan 2013 | A1 |
| 20140170086 | Pan et al. | Jun 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 101172956 | May 2008 | CN |
| 101172956 | May 2008 | CN |
| 101172956 | May 2008 | CN |
| 101606639 | Dec 2009 | CN |
| 102811698 | Dec 2012 | CN |
| 103156073 | Jun 2013 | CN |
| 103535536 | Jan 2014 | CN |
| 735096 | May 1943 | DE |
| 0083486 | Dec 1982 | EP |
| 0108937 | May 1984 | EP |
| 0508524 | Oct 1992 | EP |
| 0514553 | Nov 1992 | EP |
| 0842664 | May 1998 | EP |
| 1021158 | Jul 2000 | EP |
| 1064946 | Jan 2001 | EP |
| 1203575 | May 2002 | EP |
| 1319394 | Jun 2003 | EP |
| 1935395 | Jun 2008 | EP |
| 1529775 | May 2011 | EP |
| 2241301 | May 1975 | FR |
| 2052978 | Feb 1981 | GB |
| 2109685 | Jun 1983 | GB |
| 2243775 | Nov 1991 | GB |
| S57-158724 | Sep 1982 | JP |
| 2000-191416 | Jul 2000 | JP |
| 2004175790 | Jun 2004 | JP |
| 2009084201 | Apr 2009 | JP |
| 2010132639 | Jun 2010 | JP |
| WO8600004 | Jan 1986 | WO |
| WO9917735 | Apr 1999 | WO |
| WO199917735 | Apr 1999 | WO |
| WO0169087 | Sep 2001 | WO |
| WO2004054531 | Jul 2004 | WO |
| WO2004064536 | Aug 2004 | WO |
| WO2007063507 | Jun 2007 | WO |
| WO2011053291 | May 2011 | WO |
| WO2011088199 | Jul 2011 | WO |
| WO2011123123 | Oct 2011 | WO |
| WO2014098813 | Jun 2014 | WO |
| WO2014098814 | Jun 2014 | WO |
| WO2014098818 | Jun 2014 | WO |
| WO2014098819 | Jun 2014 | WO |
| WO2014098821 | Jun 2014 | WO |
| WO2014098822 | Jun 2014 | WO |
| WO2014098824 | Jun 2014 | WO |
| WO2014099164 | Jun 2014 | WO |
| WO2014099165 | Jun 2014 | WO |
| WO2014099166 | Jun 2014 | WO |
| WO2014099167 | Jun 2014 | WO |
| WO2014098825 | Jun 2014 | WO |
| WO2014098826 | Jun 2014 | WO |
| WO2014098828 | Jun 2014 | WO |
| WO2014098829 | Jun 2014 | WO |
| WO2014099039 | Jun 2014 | WO |
| WO2014099226 | Jun 2014 | WO |
| WO2014204439 | Dec 2014 | WO |
| Entry |
|---|
| Machine translation of CN-101172956-A (Year: 2017). |
| Zhu Zhi-guo, Jin Zhongsheng, Liu Ju-tao, Liu Wei-ming, and Ma Degui. Synthesis and Crystal Structure of (Zn+[H2N(CH2)4CH(NH2)COONa)2 S04 ]—H20. Chinese Science Bulletin Sep. 1990, vol. 36 No. 18, pp. 1521-1525. |
| Machine translation of CN 101172956-A from Google. |
| Wang, “Research of synthesis process for a new type laminate amihypertensives.” Journal of Chemical Industry & Engineering, Apr. 2012, 33(2):38-40. |
| Number | Date | Country | |
|---|---|---|---|
| 20190117536 A1 | Apr 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15668857 | Aug 2017 | US |
| Child | 16225588 | US | |
| Parent | 14653314 | US | |
| Child | 15668857 | US |
